Handelsavisen
prelaunch
Companies Healthcare ALIMP.PA
AL
ALIMP.PA Euronext Paris Medical Equipment, Supplies & Distribution

Implanet

€0,17
Open in Charts → Attach watcher ⌖
EUR
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-34,0 %
ROE
-1 084,7 %
Net margin
-35,1 %
Debt / equity
14,66
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

ALIMP.PA operates in the healthcare services and equipment industry, primarily engaged in medical equipment, supplies, and distribution.

Business. ALIMP.PA is a healthcare company operating in the Medical Equipment, Supplies & Distribution industry, primarily engaged in the sale of medical products. The firm is headquartered in France and is listed on the Euronext Paris exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
ActivityHealthcare Services & Equipment
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-1 084,7 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ALIMP.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ALIMP.PA. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    ALIMP.PA is a healthcare company operating in the Medical Equipment, Supplies & Distribution industry, primarily engaged in the sale of medical products. The firm is headquartered in France and is listed on the Euronext Paris exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryMedical Equipment, Supplies & Distribution
    ActivityHealthcare Services & Equipment
    AI synthesis
    GENERATED

    ALIMP.PA exhibits a highly leveraged capital structure, with a debt-to-equity ratio of 14.66, indicating a significant reliance on debt financing. The company's liquidity position is weak, as evidenced by a current ratio of 0.8, suggesting that it may struggle to meet short-term obligations. Additionally, the company has negative net cash after subtracting total debt, further highlighting its liquidity challenges.

    Profitability metrics for ALIMP.PA are severely negative, with a return on equity of -10.85 and a return on assets of -0.24, both well below industry norms. The company reported an operating loss of EUR -4.24 million and a net loss of EUR -4.38 million, indicating a lack of operational efficiency and profitability. These figures suggest that the company is not generating sufficient returns to justify its capital structure or meet investor expectations.

    The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. There is no indication of geographic diversification, and the company's exposure to regional markets is not disclosed. This lack of diversification could expose the company to higher risk if demand in its primary market declines.

    ALIMP.PA's growth trajectory is negative, with no indication of revenue growth in the current fiscal year. The company's operating cash flow is negative at EUR -590,000, and free cash flow is also negative at EUR -4.21 million, indicating a lack of cash generation. The company's capital expenditures of EUR -1.17 million suggest ongoing investment, but without corresponding revenue growth, these expenditures may not be justified.

    The company faces medium liquidity risk due to its weak current ratio and negative net cash position. While dilution risk is currently low, the company's high debt levels and negative equity could necessitate future equity issuance, which would dilute existing shareholders. The risk assessment highlights the need for close monitoring of the company's liquidity and capital structure.

    Recent events, including the latest financial results, show continued losses and negative cash flows. The company's last actual EPS was -0.36 EUR, and its last actual revenue was EUR 6.14 million, indicating a lack of improvement in its financial performance. No recent filings or transcripts are available to provide additional context on the company's strategic direction or operational changes.

    Key takeaways
    • ALIMP.PA is highly leveraged with a debt-to-equity ratio of 14.66, indicating a significant reliance on debt financing.
    • The company is unprofitable, with a return on equity of -10.85 and a return on assets of -0.24.
    • ALIMP.PA has a weak liquidity position, as evidenced by a current ratio of 0.8 and negative net cash after subtracting total debt.
    • The company's growth trajectory is negative, with no indication of revenue growth and negative operating and free cash flows.
    • The company faces medium liquidity risk and potential dilution risk due to its high debt levels and negative equity.
    • "margin_outlook_rationale": "The company's operating and net margins are negative, indicating a lack of profitability and potential for margin improvement.",

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    €0,17
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    €404.0k
    Net cash
    -€5.9M
    Current ratio
    0.8
    Debt / equity
    14.7
    ROA
    -23.8%
    ROE
    -10.8%
    Cash conversion
    13.0%
    CapEx / revenue
    -9.4%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-34,0 %Bottom quartile
    Net Margin-35,1 %Bottom quartile
    ROE-1 084,7 %Bottom quartile
    Capex / Rev-9,4 %Below median
    D/E14,66Bottom quartile
    Cash Conv0,13Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • ALIMP.PA Market data — financials · 2026-05-27
    • Implanet SA Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ALIMP.PACanonical
    Euronext Paris · EUR

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage